Search

Your search keyword '"Csernok, E"' showing total 89 results

Search Constraints

Start Over You searched for: Author "Csernok, E" Remove constraint Author: "Csernok, E" Topic granulomatosis with polyangiitis Remove constraint Topic: granulomatosis with polyangiitis
89 results on '"Csernok, E"'

Search Results

1. Spectrum of ANCA-specificities in eosinophilic granulomatosis with polyangiitis. A retrospective multicentre study.

2. Autoantibody profile in eosinophilic granulomatosis and polyangiitis: predominance of anti-alpha-enolase antibodies.

3. 2020 international consensus on ANCA testing beyond systemic vasculitis.

4. Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis.

7. Immune stimulatory effects of neutrophil extracellular traps in granulomatosis with polyangiitis.

8. Evaluation of automated multi-parametric indirect immunofluorescence assays to detect anti-neutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

9. Plasma cells within granulomatous inflammation display signs pointing to autoreactivity and destruction in granulomatosis with polyangiitis.

10. Current understanding of the pathogenesis of granulomatosis with polyangiitis (Wegener's).

11. Cartilage destruction in granulomatosis with polyangiitis (Wegener's granulomatosis) is mediated by human fibroblasts after transplantation into immunodeficient mice.

12. Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener's).

13. Distinct proteinase 3-induced cytokine patterns in Wegener´s granulomatosis, Churg-Strauss syndrome, and healthy controls.

14. Use of highly sensitive C-reactive protein for followup of Wegener's granulomatosis.

15. Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage?

17. Lower numbers of FoxP3 and CCR4 co-expressing cells in an elevated subpopulation of CD4+CD25high regulatory T cells from Wegener's granulomatosis.

18. Membrane proteinase 3 (mPR3) expression on neutrophils is not increased in localized Wegener's granulomatosis (WG) and Churg-Strauss syndrome (CSS).

19. The role of proteinase 3 (PR3) and the protease-activated receptor-2 (PAR-2) pathway in dendritic cell (DC) maturation of human-DC-like monocytes and murine DC.

20. Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener s granulomatosis as compared to rheumatoid arthritis and chronic Rhinosinusitis with nasal polyps.

21. Pathways to ANCA production: from differentiation of dendritic cells by proteinase 3 to B lymphocyte maturation in Wegener's granuloma.

22. Expansion of circulating NKG2D+ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's granulomatosis.

23. Proteinase 3, protease-activated receptor-2 and interleukin-32: linking innate and autoimmunity in Wegener's granulomatosis.

24. A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3.

25. Effector memory T cells as driving force of granuloma formation and autoimmunity in Wegener's granulomatosis.

26. On the Wegener granulomatosis associated region on chromosome 6p21.3.

27. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis.

28. Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off?

29. Association study with Wegener granulomatosis of the human phospholipase Cgamma2 gene.

30. Association study of Wegener granulomatosis and the functionally relevant A645G polymorphism in the bactericidal/permeability increasing protein (BPI) gene.

31. Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen.

32. New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes.

33. Frequency of proteinase 3 (PR3)-specific autoreactive T cells determined by cytokine flow cytometry in Wegener's granulomatosis.

34. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study.

35. Alterations in the phenotype of CMV-specific and total CD8+ T-cell populations in Wegener's granulomatosis.

36. Differences in CCR5 expression on peripheral blood CD4+CD28- T-cells and in granulomatous lesions between localized and generalized Wegener's granulomatosis.

37. Heterogeneity of CD4 and CD8+ memory T cells in localized and generalized Wegener's granulomatosis.

38. A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangiitis.

39. [New aspects of antineutrophil cytoplasmic antibody (ANCA) diagnosis in vasculitis].

40. Wegener's granulomatosis: antiproteinase 3 antibodies induce monocyte cytokine and prostanoid release-role of autocrine cell activation.

41. Vitronectin- and fibronectin-containing immune complexes in primary systemic vasculitis.

42. Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis.

43. Elevated monocytic IL-12 and TNF-alpha production in Wegener's granulomatosis is normalized by cyclophosphamide and corticosteroid therapy.

44. Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis.

45. CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener's granulomatosis.

46. Amphipathic variable region heavy chain peptides derived from monoclonal human Wegener's anti-PR3 antibodies stimulate lymphocytes from patients with Wegener's granulomatosis and microscopic polyangiitis.

47. Opsonization of apoptotic neutrophils by anti-neutrophil cytoplasmic antibodies (ANCA) leads to enhanced uptake by macrophages and increased release of tumour necrosis factor-alpha (TNF-alpha).

48. Localized Wegener's granulomatosis: predominance of CD26 and IFN-gamma expression.

49. Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides.

50. Anticardiolipin antibodies and antibodies to beta(2)-glycoprotein I in patients with Wegener's granulomatosis.

Catalog

Books, media, physical & digital resources